Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Novartis Halts Delivery to Second German Drug Wholesaler

Nov. 24 (Bloomberg) -- Novartis AG has stopped deliveries to a second German wholesaler over a disagreement on prices for its medicines.

The Swiss drugmaker stopped shipping to Phoenix Pharmahandel GmbH, Germany’s largest drug wholesaler, mid-month due to a disagreement over delivery conditions, Phoenix said in a statement today. Novartis also stopped deliveries of certain medicines to GEHE Pharma Handel GmbH, another German wholesaler, as of Oct. 15, GEHE’s parent company Celesio AG said in a statement Nov. 9.

Novartis has been “optimizing” its contracts with wholesalers and adjusting “many-years-old discount rules” that were outdated and no longer in line with the market, Eric Althoff, a spokesman for the Basel-based company, said in an e-mailed statement on Nov. 9. The new contracts offer a more favorable interest rate than the current market rate, he said.

“The price conditions presented by Novartis were unreasonable in Phoenix’s view and therefore couldn’t be accepted,” Phoenix said today.

Phoenix and Celesio said they have asked Novartis to resume deliveries. Novartis is continuing contract talks with some wholesalers over an “acceptable package for both sides,” Althoff said today in an e-mail. He declined to name the wholesalers.

Phoenix distributes medicines to 10,000 pharmacies in Germany, the company said in the statement.

To contact the reporter on this story: Allison Connolly in Frankfurt at aconnolly4@bloomberg.net.

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.